Calibrant Announces Ovarian and Breast Cancer Drug Discovery Partnership with Yale University.GAITHERSBURG, Md. -- Calibrant Biosystems today announced a research collaboration with the Yale University Yale University, at New Haven, Conn.; coeducational. Chartered as a collegiate school for men in 1701 largely as a result of the efforts of James Pierpont, it opened at Killingworth (now Clinton) in 1702, moved (1707) to Saybrook (now Old Saybrook), and in 1716 was School of Medicine to identify novel ovarian ovarian /ovar·i·an/ (o-var´e-an) pertaining to an ovary or ovaries. ovarian pertaining to an ovary. ovarian agenesis and breast cancer drug targets from clinical tissue specimens using Calibrant's Gemini proteomics platform. Calibrant will identify proteins and protein networks involved in ovarian and breast cancer, as well as select novel therapeutic targets found to be central to disease progression. "Our collaboration with Dr. Tavasolli at Yale University contributes substantially to our gynecologic gynecologic /gy·ne·co·log·ic/ (gi?ne-) (jin?e-kah-loj´ik) pertaining to the female reproductive tract or to gynecology. and breast cancer drug programs," stated Dr. Brian Balgley, Chief Technology Officer of Calibrant Biosystems. "This partnership is enabling effective identification of disease-relevant pathways and drug targets by applying Calibrant's Gemini platform to targeted discovery from selected cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer ." Dr. Fattaneh Tavasolli, Calibrant's collaborator at the Yale University School of Medicine, is Professor of Pathology and Director of the Women's Health Women's Health Definition Women's health is the effect of gender on disease and health that encompasses a broad range of biological and psychosocial issues. Program/Gynecology and Breast Pathology. Calibrant has recently established several drug discovery collaborations with world-renowned medical research centers this year, leading to active therapeutic programs for cancer indications including ovarian and primary brain cancer. About Calibrant Biosystems Calibrant Biosystems is a Gaithersburg, MD biotechnology company specializing in targeted drug discovery from clinical tissue specimens. Calibrant's advanced Gemini discovery platform, which is compatible with both fresh and formalin-fixed archival tissues, provides the unique ability to comparatively map protein networks between different cell types within a single tissue section. With an initial focus on monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing drug development in oncology, Calibrant is leveraging the Gemini platform for the development of first-in-class therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. across a range of cancer indications. More information is available at www.calibrant.com. Note: Gemini is a trademark of Calibrant Biosystems. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion